middle.news

Orthocell Boosts Cash by $3M to Accelerate Nerve Repair Product Rollout

1:12pm on Wednesday 18th of February, 2026 AEDT Healthcare
Read Story

Orthocell Boosts Cash by $3M to Accelerate Nerve Repair Product Rollout

1:12pm on Wednesday 18th of February, 2026 AEDT
Key Points
  • Received $3 million R&D tax refund from Australian Government
  • Cash reserves now total $49.6 million, with zero debt
  • Funding supports commercial expansion of Remplir™ in Americas and Asia Pacific
  • Ongoing investment in clinical evidence and medical education
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Orthocell (ASX:OCC)
OPEN ARTICLE